Trial Profile
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of FG-3019 in Subjects With Type 2 Diabetes Mellitus (DM) and Persistent Proteinuria on Background Angiotensin Converting Enzyme Inhibitor (ACEi) and/or Angiotensin II Receptor Blockade (ARB) Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pamrevlumab (Primary)
- Indications Diabetic nephropathies; Proteinuria
- Focus Therapeutic Use
- Sponsors FibroGen
- 10 Jan 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Jun 2009 New trial record